21/05/26

Register for De Brauw x hollandbio: Scaling Beyond Series C

Late-stage biotech companies (Series C/D and beyond) face fundamentally different challenges compared to early-stage biotech ventures. Funding rounds become larger and more complex, investors apply stricter requirements, and governance and cross-border considerations carry greater weight.

Access to growth capital is not only crucial for biotech companies to grow and expand, but also helps strengthen the funding environment for and is essential to maintain the Netherlands’ international competitive position.

During this event, we bring together strategic insights from investors, bankers, and lawyers, share company perspectives on late-stage financing options, and inform you about different strategies to attract growth capital.

Program

15:30 – 16:00 Walk in with coffee and tea
16:00 – 16:10 Welcoming words by De Brauw & hollandbio
16:10 – 17:00 Panel discussion.
17:00 – Networking drinks

Our panelists:

Moderator: Jaap Barneveld (Partner at De Brauw Blackstone Westbroek). Panel members: Ellen Lefever (General Counsel at Agomab Therapeutics), Zosia van Eesteren (Senior Associate at Gilde Healthcare), Jan Christoph Vollgraff (Vice President Healthcare Investment Banking at Van Lanschot Kempen), and Oscar Marshall (Associate at EQT Group).

This event will take place on May 21 at the Amsterdam office of De Brauw Blackstone Westbroek.

Visiting address: Burgerweeshuispad 201, 1076 GR Amsterdam

We hope to see you there! Please register via the online form.

door Idalia Dlugosz